Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

928 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.
Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Ravina B, et al. Among authors: tanner c. Mov Disord. 2012 Sep 15;27(11):1392-7. doi: 10.1002/mds.25157. Epub 2012 Sep 13. Mov Disord. 2012. PMID: 22976926 Free PMC article.
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group. Shoulson I, et al. Among authors: tanner c. Ann Neurol. 2002 May;51(5):604-12. doi: 10.1002/ana.10191. Ann Neurol. 2002. PMID: 12112107 Clinical Trial.
Levodopa and the progression of Parkinson's disease.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Fahn S, et al. Among authors: tanner c. N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447. N Engl J Med. 2004. PMID: 15590952 Free article. Clinical Trial.
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators. Ravina B, et al. Among authors: tanner c. Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690. Mov Disord. 2009. PMID: 19691116
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators; Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C. Schwid SR, et al. Among authors: tanner c. Mov Disord. 2010 Sep 15;25(12):1801-8. doi: 10.1002/mds.23006. Mov Disord. 2010. PMID: 20669311 Clinical Trial.
The Parkinson Progression Marker Initiative (PPMI).
Parkinson Progression Marker Initiative. Parkinson Progression Marker Initiative. Prog Neurobiol. 2011 Dec;95(4):629-35. doi: 10.1016/j.pneurobio.2011.09.005. Epub 2011 Sep 14. Prog Neurobiol. 2011. PMID: 21930184 Free PMC article. Review.
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.
Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium. Pankratz N, et al. Among authors: tanner c. Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687. Ann Neurol. 2012. PMID: 22451204 Free PMC article.
928 results